ArticleAdvances in therapy2023

Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis.

Kun Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.